Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year.